MedTrace Logo

Stem Cells in Rapidly Evolving Active Multiple Sclerosis

NCT01606215 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-01-14

Study results available
· View outcomes & findings →

Summary

This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).

Conditions

Interventions

DRUG

Mesenchymal stem cells

1.0-2.0 million cells/kg body weight

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Paolo A Muraro, MD PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606215 on ClinicalTrials.gov